Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Non-Current Debt (2016 - 2023)

Historic Non-Current Debt for vTv Therapeutics (VTVT) over the last 10 years, with Q1 2023 value amounting to $922000.0.

  • vTv Therapeutics' Non-Current Debt rose 1974.03% to $922000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $922000.0, marking a year-over-year increase of 1974.03%. This contributed to the annual value of $684000.0 for FY2022, which is 4580.03% down from last year.
  • As of Q1 2023, vTv Therapeutics' Non-Current Debt stood at $922000.0, which was up 1974.03% from $684000.0 recorded in Q4 2022.
  • vTv Therapeutics' 5-year Non-Current Debt high stood at $4.5 million for Q1 2021, and its period low was $684000.0 during Q4 2022.
  • Its 5-year average for Non-Current Debt is $2.3 million, with a median of $2.3 million in 2021.
  • Per our database at Business Quant, vTv Therapeutics' Non-Current Debt skyrocketed by 6151.03% in 2020 and then crashed by 8296.08% in 2022.
  • vTv Therapeutics' Non-Current Debt (Quarter) stood at $2.6 million in 2019, then rose by 10.38% to $2.9 million in 2020, then tumbled by 56.04% to $1.3 million in 2021, then crashed by 45.8% to $684000.0 in 2022, then surged by 34.8% to $922000.0 in 2023.
  • Its Non-Current Debt stands at $922000.0 for Q1 2023, versus $684000.0 for Q4 2022 and $1.4 million for Q3 2022.